14.27
-3.64(-20.32%)
Currency In USD
Address
One Commerce Square
Philadelphia, PA 19103
United States of America
Phone
267 866 0311
Website
Sector
Healthcare
Industry
Biotechnology
Employees
60
First IPO Date
February 28, 2020
| Name | Title | Pay | Year Born |
| William Chou | President, Chief Executive Officer & Director | 990,111 | 1973 |
| Kathleen Borthwick | Senior Vice President, Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 604,727 | 1977 |
| Karl Whitney | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Sue Browne | Chief Scientific Officer | 0 | N/A |
| Eden Fucci | Senior Vice President of Technical Operations | 0 | N/A |
| Stuart Henderson | Chief Business Officer | 0 | N/A |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.